<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients with severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi>, <z:hpo ids='HP_0100806'>sepsis</z:hpo> mortality is reduced by treatment with granulocyte colony-stimulating factor (G-CSF), but myelodsyplastic syndrome and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) have been reported </plain></SENT>
<SENT sid="1" pm="."><plain>We studied 374 patients with <z:chebi fb="0" ids="18022">SCN</z:chebi> and 29 patients with <z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>) on long-term G-CSF enrolled in the Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> International Registry </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:chebi fb="0" ids="18022">SCN</z:chebi>, <z:hpo ids='HP_0100806'>sepsis</z:hpo> mortality was stable at 0.9% per year </plain></SENT>
<SENT sid="3" pm="."><plain>The hazard of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> increased significantly over time, from 2.9% per year after 6 years to 8.0% per year after 12 years on G-CSF </plain></SENT>
<SENT sid="4" pm="."><plain>After 10 years, the cumulative incidence was 8% for <z:hpo ids='HP_0100806'>sepsis</z:hpo> mortality and 21% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>A subgroup of <z:chebi fb="0" ids="18022">SCN</z:chebi> patients (29%) received more than the median dose of G-CSF (&gt; or = 8 microg/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC &lt; 2.188 x 10(9)/L [2188/microL] at 6-18 months) </plain></SENT>
<SENT sid="6" pm="."><plain>In these less-responsive patients, the cumulative incidence of adverse events was highest: after 10 years, 40% developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 14% died of <z:hpo ids='HP_0100806'>sepsis</z:hpo>, compared with 11% and 4%, respectively, of more responsive patients whose ANC was above the median on doses of G-CSF below the median </plain></SENT>
<SENT sid="7" pm="."><plain>Risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may be similar in <z:chebi fb="26" ids="8984">SDS</z:chebi> and <z:chebi fb="0" ids="18022">SCN </z:chebi></plain></SENT>
<SENT sid="8" pm="."><plain>In less-responsive <z:chebi fb="0" ids="18022">SCN</z:chebi> patients, early hematopoietic stem cell transplantation may be a rational option </plain></SENT>
</text></document>